SI3222272T1 - Farmacevtski pripravek karbetocina - Google Patents

Farmacevtski pripravek karbetocina

Info

Publication number
SI3222272T1
SI3222272T1 SI201132022T SI201132022T SI3222272T1 SI 3222272 T1 SI3222272 T1 SI 3222272T1 SI 201132022 T SI201132022 T SI 201132022T SI 201132022 T SI201132022 T SI 201132022T SI 3222272 T1 SI3222272 T1 SI 3222272T1
Authority
SI
Slovenia
Prior art keywords
carbetocin
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
SI201132022T
Other languages
English (en)
Inventor
Anders Nilsson
Mattias Malm
Kazimierz Wisniewski
Britta Siekmann
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3222272(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of SI3222272T1 publication Critical patent/SI3222272T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
SI201132022T 2010-09-30 2011-09-29 Farmacevtski pripravek karbetocina SI3222272T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30
EP17169328.6A EP3222272B1 (en) 2010-09-30 2011-09-29 Pharmaceutical composition of carbetocin

Publications (1)

Publication Number Publication Date
SI3222272T1 true SI3222272T1 (sl) 2022-01-31

Family

ID=43478408

Family Applications (3)

Application Number Title Priority Date Filing Date
SI201131272T SI2621468T1 (sl) 2010-09-30 2011-09-29 Farmacevtski sestavki karbetokina
SI201132022T SI3222272T1 (sl) 2010-09-30 2011-09-29 Farmacevtski pripravek karbetocina
SI201132035T SI3246018T1 (sl) 2010-09-30 2011-09-29 Farmacevtski sestavek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201131272T SI2621468T1 (sl) 2010-09-30 2011-09-29 Farmacevtski sestavki karbetokina

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201132035T SI3246018T1 (sl) 2010-09-30 2011-09-29 Farmacevtski sestavek

Country Status (26)

Country Link
US (4) US9566311B2 (sl)
EP (5) EP4374878A2 (sl)
JP (2) JP6038797B2 (sl)
KR (2) KR102102664B1 (sl)
CN (4) CN107080832B (sl)
AU (1) AU2011309762B2 (sl)
BR (2) BR122021001123B1 (sl)
CA (1) CA2812510A1 (sl)
CY (2) CY1119245T1 (sl)
DK (3) DK2621468T3 (sl)
ES (3) ES2637988T3 (sl)
HK (1) HK1246170A1 (sl)
HR (2) HRP20211969T1 (sl)
HU (3) HUE056835T2 (sl)
IL (3) IL225238B (sl)
JO (3) JO3400B1 (sl)
LT (2) LT2621468T (sl)
MX (1) MX352949B (sl)
NZ (1) NZ609719A (sl)
PL (3) PL2621468T3 (sl)
PT (3) PT3222272T (sl)
RS (2) RS56220B1 (sl)
RU (2) RU2604690C2 (sl)
SI (3) SI2621468T1 (sl)
TW (6) TWI650134B (sl)
WO (1) WO2012042371A2 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ701419A (en) * 2012-05-08 2016-04-29 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
EP3193907B1 (en) * 2014-09-19 2020-01-01 Ferring BV Method of treating prader-willi syndrome
ES2821822T3 (es) 2014-10-01 2021-04-27 Oxytone Bioscience B V Unidad de dosificación farmacéutica sólida desintegrante por vía oral que contiene una sustancia de control de partos
CN106999436B (zh) 2014-10-01 2021-07-02 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
EP3242676B1 (en) 2015-01-07 2023-10-04 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
CN109414476B (zh) 2016-04-12 2023-01-31 三叉神经股份公司 含镁催产素制剂和应用方法
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
AU2018312956B2 (en) * 2017-08-11 2022-03-10 Ferring B.V. Method of manufacturing a pharmaceutical composition
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
US11970554B2 (en) 2018-03-01 2024-04-30 Tonix Pharmaceuticals Holding Corp. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
WO2020061414A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
JP7390031B2 (ja) 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
MX2021015732A (es) 2019-11-04 2022-01-24 Ferring Bv Administracion intranasal de merotocina para mejorar la lactancia.
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
JP2024511199A (ja) 2021-03-26 2024-03-12 オーティーフォービー 嚥下障害の治療
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DK0916347T3 (da) 1997-11-18 2003-04-22 Uni Pharma Kleon Tsetis A B E Farmaceutiske injicerbare opløsninger der indeholder paracetamol og kombinationer af paracetamol med andre aktive bestanddele
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
JP2001233787A (ja) 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
DK1441589T3 (da) 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
DE60333857D1 (de) 2002-10-03 2010-09-30 Neuropharmacology Services Llc Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
US20040224886A1 (en) 2003-01-08 2004-11-11 Chiron Corporation Stabilized compositions comprising tissue factor pathway inhibitor protein or tissue factor pathway inhibitor variant proteins
US20100143485A1 (en) 2003-03-05 2010-06-10 Hudnut Paul S Oxycontin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
MY161661A (en) 2007-07-02 2017-04-28 Sime Darby Malaysia Berhad Vegetable fat blend and edible products containing such a fat blend
ES2319054B1 (es) * 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
MX2010010743A (es) * 2008-03-31 2010-11-04 Ferring Bv Analogos de oxitocina.
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Also Published As

Publication number Publication date
CN107080832B (zh) 2021-05-07
BR122021001123B1 (pt) 2021-05-18
IL245328B (en) 2022-04-01
HUE034367T2 (en) 2018-02-28
JP6038797B2 (ja) 2016-12-07
HK1246170A1 (zh) 2018-09-07
LT2621468T (lt) 2017-11-27
TWI750934B (zh) 2021-12-21
BR112013007362B1 (pt) 2021-05-25
US20130210746A1 (en) 2013-08-15
KR102102664B1 (ko) 2020-04-22
SI2621468T1 (sl) 2017-10-30
RS56220B1 (sr) 2017-11-30
CA2812510A1 (en) 2012-04-05
RU2016143751A (ru) 2018-12-18
EP3222272A1 (en) 2017-09-27
EP3246018A1 (en) 2017-11-22
JO3400B1 (ar) 2019-10-20
CY1124924T1 (el) 2023-01-05
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
JOP20180102B1 (ar) 2022-03-14
JP2017048226A (ja) 2017-03-09
SI3246018T1 (sl) 2022-02-28
US20170106044A1 (en) 2017-04-20
EP3222272B1 (en) 2021-11-03
HRP20171256T1 (hr) 2017-10-20
EP4374878A2 (en) 2024-05-29
EP3936117A1 (en) 2022-01-12
JP2013543492A (ja) 2013-12-05
EP3246018B1 (en) 2021-11-03
IL245326B (en) 2021-04-29
US20230124105A1 (en) 2023-04-20
WO2012042371A2 (en) 2012-04-05
JOP20180103B1 (ar) 2022-03-14
DK3222272T3 (da) 2022-01-24
JOP20180102A1 (ar) 2019-01-30
PL3246018T3 (pl) 2022-05-02
DK2621468T3 (en) 2017-09-11
CN104906032A (zh) 2015-09-16
ES2637988T3 (es) 2017-10-18
TWI650134B (zh) 2019-02-11
EP2621468B1 (en) 2017-06-14
LT3222272T (lt) 2021-12-27
TW201605466A (zh) 2016-02-16
CN103124554A (zh) 2013-05-29
JP6250770B2 (ja) 2017-12-20
AU2011309762B2 (en) 2014-07-17
HUE056835T2 (hu) 2022-03-28
IL225238A0 (en) 2013-06-27
IL245326A0 (en) 2016-06-30
CN107412728A (zh) 2017-12-01
RS62873B1 (sr) 2022-02-28
HRP20211969T1 (hr) 2022-03-18
TW202112389A (zh) 2021-04-01
TW201729797A (zh) 2017-09-01
PL2621468T3 (pl) 2017-11-30
IL245328A0 (en) 2016-06-30
AU2011309762A1 (en) 2013-04-04
RU2013112666A (ru) 2014-11-10
CY1119245T1 (el) 2018-02-14
PL3222272T3 (pl) 2022-03-07
KR20180123599A (ko) 2018-11-16
TWI680773B (zh) 2020-01-01
MX2013003365A (es) 2013-07-29
JOP20180103A1 (ar) 2019-01-30
PT3246018T (pt) 2022-01-13
TWI532507B (zh) 2016-05-11
PT2621468T (pt) 2017-09-08
TW201605465A (zh) 2016-02-16
US20170106043A1 (en) 2017-04-20
DK3246018T3 (da) 2022-01-17
BR112013007362A2 (pt) 2016-07-12
NZ609719A (en) 2014-07-25
ES2905561T3 (es) 2022-04-11
EP2621468A2 (en) 2013-08-07
ES2902418T3 (es) 2022-03-28
RU2737264C2 (ru) 2020-11-26
MX352949B (es) 2017-12-15
KR101919119B1 (ko) 2018-11-15
TWI661834B (zh) 2019-06-11
KR20130136467A (ko) 2013-12-12
HUE057187T2 (hu) 2022-04-28
RU2016143751A3 (sl) 2020-01-16
CN107080832A (zh) 2017-08-22
IL225238B (en) 2018-07-31
US9566311B2 (en) 2017-02-14
TW201940188A (zh) 2019-10-16
RU2604690C2 (ru) 2016-12-10
TWI746951B (zh) 2021-11-21
WO2012042371A3 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
HK1246170A1 (zh) 藥物組合物
IL225457A0 (en) Pharmaceutical composition
RS55566B1 (sr) Farmaceutska kompozicija
LT2616076T (lt) Farmacinės kompozicijos
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
EP2635307A4 (en) PHARMACEUTICAL COMPOSITIONS
IL221501A (en) Medicinal product containing miramistine
GB201001911D0 (en) Pharmaceutical composition
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
IL226378A0 (en) preparations@rokkhot
GB201019775D0 (en) Pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition
GB201008590D0 (en) Pharmaceutical compositions